AP2957A - New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs - Google Patents

New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs

Info

Publication number
AP2957A
AP2957A AP2010005249A AP2010005249A AP2957A AP 2957 A AP2957 A AP 2957A AP 2010005249 A AP2010005249 A AP 2010005249A AP 2010005249 A AP2010005249 A AP 2010005249A AP 2957 A AP2957 A AP 2957A
Authority
AP
ARIPO
Prior art keywords
drugs
beta
antibodies specific
diagnostic agents
amyloid peptides
Prior art date
Application number
AP2010005249A
Other languages
English (en)
Other versions
AP2010005249A0 (en
Inventor
Eugeen Vanmechelen
Pierre Grognait
Nicolas Sergent
Original Assignee
Inst Nat Sante Rech Med
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Sanofi Aventis filed Critical Inst Nat Sante Rech Med
Publication of AP2010005249A0 publication Critical patent/AP2010005249A0/en
Application granted granted Critical
Publication of AP2957A publication Critical patent/AP2957A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2010005249A 2007-10-29 2008-10-24 New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs AP2957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29
PCT/EP2008/064432 WO2009056490A1 (en) 2007-10-29 2008-10-24 NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS

Publications (2)

Publication Number Publication Date
AP2010005249A0 AP2010005249A0 (en) 2010-06-30
AP2957A true AP2957A (en) 2014-08-31

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005249A AP2957A (en) 2007-10-29 2008-10-24 New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs

Country Status (27)

Country Link
US (1) US8343493B2 (ar)
EP (1) EP2205633A1 (ar)
JP (1) JP5421277B2 (ar)
KR (1) KR20100097651A (ar)
CN (1) CN101883792B (ar)
AP (1) AP2957A (ar)
AR (1) AR069085A1 (ar)
AU (1) AU2008317705B2 (ar)
CA (1) CA2703825A1 (ar)
CL (1) CL2008003197A1 (ar)
CO (1) CO6270369A2 (ar)
CR (1) CR11396A (ar)
EA (1) EA201070539A1 (ar)
EC (1) ECSP10010142A (ar)
HN (1) HN2010000880A (ar)
IL (1) IL205398A0 (ar)
MA (1) MA31793B1 (ar)
MX (1) MX2010004660A (ar)
MY (1) MY155144A (ar)
NI (1) NI201000075A (ar)
NZ (1) NZ585000A (ar)
TN (1) TN2010000197A1 (ar)
TW (1) TW200936605A (ar)
UA (1) UA103602C2 (ar)
UY (1) UY31433A1 (ar)
WO (1) WO2009056490A1 (ar)
ZA (1) ZA201002989B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN102781962B (zh) 2010-03-03 2014-12-10 阿布林克斯公司 双互补位A-β结合多肽
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
BR112013033258B1 (pt) 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10774120B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN118382636A (zh) * 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
'Antibodies to Beta Amyloid Proteins" INTERNET CITATION, [Online] 3 June 2002 (2002-06-03), XP002257888 Retrieved from the Internet: URL:http://web.archive.org/web/20020623071 147/www.alzforum.org/members/re sources/antibodies/Beta-Amyloid/page_set.h tml> *

Also Published As

Publication number Publication date
US8343493B2 (en) 2013-01-01
HN2010000880A (es) 2014-03-10
TW200936605A (en) 2009-09-01
UA103602C2 (ru) 2013-11-11
AR069085A1 (es) 2009-12-30
CR11396A (es) 2012-10-18
WO2009056490A1 (en) 2009-05-07
JP2011502139A (ja) 2011-01-20
CN101883792B (zh) 2014-08-27
MX2010004660A (es) 2010-07-30
AU2008317705B2 (en) 2014-06-05
KR20100097651A (ko) 2010-09-03
EA201070539A1 (ru) 2010-10-29
MY155144A (en) 2015-09-15
JP5421277B2 (ja) 2014-02-19
IL205398A0 (en) 2010-12-30
AP2010005249A0 (en) 2010-06-30
NZ585000A (en) 2012-08-31
CO6270369A2 (es) 2011-04-20
CL2008003197A1 (es) 2010-01-15
CA2703825A1 (en) 2009-05-07
MA31793B1 (ar) 2010-10-01
US20110059092A1 (en) 2011-03-10
AU2008317705A1 (en) 2009-05-07
UY31433A1 (es) 2009-05-29
TN2010000197A1 (en) 2011-11-11
ECSP10010142A (es) 2010-07-30
ZA201002989B (en) 2011-07-27
NI201000075A (es) 2010-09-23
CN101883792A (zh) 2010-11-10
EP2205633A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
AP2957A (en) New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs
IL254157B (en) 3–14–eta antibodies and their uses for the diagnosis and treatment of arthritis
HK1202558A1 (en) Compositions and methods for the therapy and diagnosis of influenza
ZA201102004B (en) Antibodies against human il 17 and uses thereof
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
EP2097534A4 (en) HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
HK1244823A1 (zh) 用於原生原纖維形式β-澱粉樣蛋白的特定抗體
IL207245A0 (en) Alpha 5-beta 1 antibodies and their uses
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
ZA200906516B (en) Novel human anti-R7V antibodies and uses thereof
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
GB2458080B (en) Sterols modified by polyethylene glycol, the preparation and the use thereof
EP2097093A4 (en) THERAPEUTIC AND DIAGNOSTIC PEPTIDES
GB0508356D0 (en) Materials and methods relating to the diagnosis of cancer
EP2275437A4 (en) POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE POLYPEPTIDE
EP2194062A4 (en) CYCLIC HEPTAPEPTIDE AND USE THEREOF
PL380011A1 (pl) Nowe szkieletowe preparaty białkowe, sposób ich otrzymywania oraz zastosowania
GB0715513D0 (en) The medicinal uses of molecules and their derivatives
GB0616531D0 (en) The medicinal uses of molecules and their derivatives
PL381879A1 (pl) Postać preparatu farmaceutycznego oraz sposób jej otrzymywania
GB0516750D0 (en) The medicinal uses of molecules and their derivatives
GB0821489D0 (en) The medicinal uses of molecules and their derivatives